Drug Profile
TPIV 110
Alternative Names: TPIV110Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Marker Therapeutics Inc
- Class Antigens; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer